Transactivation by temperature-dependent p53 mutants in yeast and human cells

Cell Cycle

Volumn 9, Issue 11, 2010, Pages 2141-2148

  Slovackova, Jana ^a,b   Grochova, Diana ^a   Navratilova, Jarmila ^b   Smarda, Jan ^b   Smardova, Jana ^a,b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Discriminating p53 mutants; FASAY; p53; Temperature dependent p53 mutants; Transactivation

Indexed keywords

PROTEIN P53;

ALLELE; ARTICLE; CONTROLLED STUDY; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPORTER GENE; TEMPERATURE DEPENDENCE; TEMPERATURE MEASUREMENT;

EID: 77953564661     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.11.11808     Document Type: Article

References (24)

1. Di Como CJ, Prives C. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. Oncogene 1998; 16:2527-39. (Pubitemid 28258584)
2. Szak ST, Mays D, Pietenpol JA. Kinetics of p53 binding to promoter sites in vivo. Mol Cell Biol 2001; 21:3375-86. (Pubitemid 32381773)
3. Qian H, Wang T, Naumovski L, Lopez CD, Brachmann RK. Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites. Oncogene 2002; 21:7901-11. (Pubitemid 35398849)
4. Weinberg RL, Veprintsev DB, Bycroft M, Fersht AR. Comparative binding of p53 to its promoter and DNA recognition elements. J Mol Biol 2005; 348:589-96. (Pubitemid 40515671)
5. Blagosklonny MV. p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect. FASEB J 2000; 14:1901-7.
6. Resnick MA, Inga A. Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci USA 2003; 100:9934-9.
7. Joerger AC, Fersht AR. Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 2007; 26:2226-42.
8. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 2003; 100:8424-9.
9. Menendez D, Inga A, Resnick MA. The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes. Mol Cell Biol 2006; 26:2297-308. (Pubitemid 43346929)
10. Dearth LR, Qian H, Wang T, Baroni TE, Zeng J, Chen SW, et al. Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss-of-heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis 2007; 28:289-98. (Pubitemid 46321844)
11. Shiraishi K, Kato S, Han SY, Liu W, Otsuka K, Sakayori M, et al. Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem 2004; 279:348-55.
12. Grochova D, Vankova J, Damborsky J, Ravcukova B, Smarda J, Vojtesek B, et al. Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast. Oncogene 2008; 27:1243-52. (Pubitemid 351294697)
13. Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 2008; 105:10360-5.
14. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, et al. A simple p53 functional assay for screening cell lines, blood and tumors. Proc Natl Acad Sci USA 1995; 92:3963-7.
15. Friedler A, Veprintsev DB, Hansson LO, Fersht AR. Kinetic instability of p53 core domain mutants: implications for rescue by small molecules. J Biol Chem 2003; 278:24108-12.
16. Joerger AC, Ang HC, Fersht AR. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci USA 2006; 103:15056-61.
17. Maurici D, Monti P, Campomenosi P, North S, Frebourg T, Fronza G, et al. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay. Oncogene 2001; 20:3533-40. (Pubitemid 32619406)
18. North S, Pluquet O, Maurici D, El-Ghissassi F, Hainaut P. Restoration of wild-type conformation and activity of temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1. Mol Carcinog 2002; 33:181-8.
19. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Mol Cell Biol 2008; 9:402-12.
20. Friedlander P, Haupt Y, Prives C, Oren M. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol 1996; 16:4961-71.
21. Ludwig RL, Bates S, Vousden KH. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol 1996; 16:4952-60.
22. Campomenosi P, Monti P, Aprile A, Abbondandolo A, Frebourg T, Gold B, et al. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene 2001; 20:3573-9.
23. Chipuk JE, Green DR. Dissecting p53-dependent apoptosis. Cell Death Differ 2006; 13:994-1002.
24. Navratilova J, Horvath V, Kozubik A, Lojek A, Lipsick J, Smarda J. p53 arrests growth and induces differentiation of v-Myb-transformed monoblasts. Differentiation 2007; 75:592-604.